The prevalence of onychomycosis has been increasing over the past few years due to unhealthy lifestyle and negligence of nail care. Future Market Insights (FMI) presents a positive outlook for the onychomycosis treatment market, forecasting it to exhibit 6.1% Y-o-Y growth in 2021.
According to a recent study published by National Center for Biotechnology Information (NCBI) in May 2020, the overall prevalence of onychomycosis was approximately 5.5% in the general population.
Toenail onychomycosis are more common and requires longer duration of treatment, which can also extend to a year. Sometimes complete cure, defined as clinical cure, is unattainable, which may lead to indefinite treatment duration and consequently drive the onychomycosis treatment market. The risk of onychomycosis is 1.9 to 2.8 times higher in people with diabetes, compared with the general population. This is leading to rising revenue accumulation of drug manufacturers targeting the onychomycosis treatment market.
The increasing risk factors such as nail injury or nail surgery, diabetes, weakened immune system, blood circulation disorders, athlete’s foot or ringworm, and others are driving the onychomycosis treatment market. The growing risk of occupational hazards such as agriculture, waste disposal, and others is also propelling the growth of the onychomycosis treatment market.
Diabetes and related conditions contributing to poor peripheral circulation are the major drivers of the market. Onychomycosis may represent an important forecast for the development of diabetic foot syndrome and foot ulcers. Patients who are immunosuppressed, such as those undergoing cancer therapy and those with HIV infection also are predisposed to fungal nail infection.
Coronavirus pandemic has changed the public medical care needs and spending however this is viewed as transient effect on the onychomycosis treatment market. The increasing COVID-19 patient pool attracted spotlight to the treatment of these patients on emergency basis, consequently reducing the patient visits to the medical clinics for onychomycosis treatment.
Decreasing visits demonstrate lesser treatment reception that resulted in temporary contraction of sales. Nonetheless, demand is likely to recover in the coming years with drugs emerging as more preferred type of treatment. The drugs segment is expected to account for nearly 75% of revenue generated in the market.
Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1279
Key Takeaways from Onychomycosis Treatment Market Study
- High spending power supports growth in the U.S., sealing its dominance in North America. The U.S. is expected to account for over 84% of sales registered in the region
- The demand from the U.K. will continue rising, enabling year-on-year growth at above 7%
- Germany and France too will continue exhibiting high demand
- Within East Asia, Japan holds dominance, yet demand from China is likely to rise at a higher pace
“Market players are likely to focus on merger and acquisition to expand their footprint worldwide. They are also expected to focus on capitalizing on opportunities across emerging economies to gain competitive advantage,” said an FMI analyst.
Geriatric Population More Susceptible Onychomycosis
According to the World Health Organization (WHO), age is the key risk factor for the development of onychomycosis and the risk for onychomycosis increases with age, particularly for persons aged >50 years. Approximately, about 80-85% of onychomycosis occurs in patients aged greater than 50 years, globally. The rise in elderly population will therefore present lucrative growth opportunities to onychomycosis treatment market.
Who is Winning?
Key players in the onychomycosis treatment market are keenly focusing on strategic activities such as acquisitions, collaborations and mergers in order to create a strong position.
For Instance, In September 2018, Almirall S.A. acquired of portfolio of five products comprising of Allergan’s Medical dermatology unit in the U.S. to further enhance the company’s dermatology portfolio.
In 2017, Ziarco Group ltd. was acquired by Novartis acquired. Ziarco Group ltd. a privately held company in the U.K. The company focuses on the development of novel treatments in the field of dermatology.
Some of the key players are Sanofi S.A., Pfizer Inc., Bayer AG., Moberg Pharma AB and Cardinal Health Inc.
Want more insights?
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global onychomycosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on onychomycosis treatment market on basis of treatment type by Drug, Laser, Photodynamic Therapy, by Disease Indication (Distal Subungual Onychomycosis,White Superficial Onychomycosis, Proxima, Subungual Onychomycosis, Candidal Onychomycosis and Total Dystrophic Onychomycosis), Gender ( Male and Female), Age Group ( 0-18 years, 18-39 years, 40-64 years and 65 years and above) Distribution Channel (Institutional Sales, Retail Sales) across seven major regions.
Any Queries, ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1279
Key Questions Answered in the Report
- Which is the most lucrative market for onychomycosis treatment?
North America currently holds for the largest share in the onychomycosis treatment market. Increasing awareness regarding aesthetic appearance, expanding healthcare infrastructure and availability of advanced onychomycosis treatment is propelling growth in the region. Within North America, the U.S. is expected to emerge as a highly lucrative market.
- Which is the top-selling onychomycosis treatment?
Drug segment in the onychomycosis treatment market will continue to remain the most profitable one through the forecast period.
- Which age group will continue exhibiting high demand for onychomycosis treatment?
18-39 years age group will continue remain dominant, exhibiting considerably high demand for onychomycosis treatment. This segment contributes for more than half of the market share as the adult age group is more concerned about their aesthetic appearance.